There is only one Cardiolite

Imaging Protocols

Suggested Cardiolite® One-Day Rest/Stress1,2

Using this protocol, you can complete imaging in one day. A low-dose Cardiolite® rest study is followed by a higher-dose stress study.  The higher dose Cardiolite® in the stress study overcomes the lower dose of the rest study, permitting high-quality gated SPECT imaging.1,2

Rest Portion
  • Inject with 10 mCi of Cardiolite®
  • Administer rest injection 60–90 minutes prior to imaging
  • Upon completion of rest imaging and review for quality approval, the patient may be prepared for stress testing. Patient should wait 1–4 hours from injection before proceeding to stress portion
Stress Portion
  • Patient undergoes exercise or pharmacologic stress
  • Inject with 25–30 mCi of Cardiolite® at peak (exercise) stress, or at the specified time if a pharmacologic stress agent is used
  • Begin exercise stress scan 10–60 minutes after Cardiolite® injection
  • When using pharmacologic stress, begin imaging 45–60 minutes after Cardiolite® injection

 

One-Day Rest/Stress Algorithm

Rest Portion

Stress Portion

One-Day Rest/Stress Imaging Sequence:
  • The rest image represents a true rest perfusion image because the patient has not previously been stressed
  • One-day protocol offers convenience for patients and rapid availability of results
  • Preferable when using a 1-day protocol with a short time interval (less than 2 hours) in between
    • Note that using a dose ratio less than 1:3 will necessitate increasing the time interval between the two injections1
  • Rest/stress protocols are now perfomed almost universally with no delay between the rest and subsequent stress images.1
  • Image acquisition can be repeated if there is significant patient motion or instrument malfunction
  • The ejection fraction is a post-stress EF, not a stress EF, since the image acquisition occurs after the exercise

 

Click here to view footnotes
  1. ASNC Imaging Guidelines for Nuclear Cardiology Procedures: Stress Protocols and tracers
    Henzlova et al., Journal of Nuclear Cardiology 2009 Accessed April 13, 2010.
    http://asnc.org/imageuploads/ImagingGuidelinesStressProtocols021109.pdf
  2. Cardiolite® [package insert]. N. Billerica, MA: Lantheus Medical Imaging; 2009.

 

Lantheus Medical Imaging

Indications and Usage for Cardiolite®:
Myocardial Imaging:  CARDIOLITE® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.  CARDIOLITE® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

CONTRAINDICATIONS:
None known.

IMPORTANT SAFETY INFORMATION: 

CARDIOLITE® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.  In some patients the allergic symptoms developed on the second injection during CARDIOLITE® imaging.  The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.

WARNINGS AND PRECAUTIONS:
In studying patients in whom cardiac disease is known or suspected, care should
be taken to assure continuous monitoring and treatment in accordance with safe,
accepted clinical procedure.

Caution should be exercised and emergency equipment should be available when administering CARDIOLITE®.

Before administering CARDIOLITE® patients should be asked about the possibility of allergic reactions to either CARDIOLITE® or MIRALUMA®.
MIRALUMA® is an identical compound used in breast imaging.

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Please see full Prescribing Information: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)

Indications and Usage for Thallous Chloride Tl 201 Injection:
Thallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed Tomography) techniques for the diagnosis and localization of myocardial infarction.  It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect.

Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease).

It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia.

Thallous Chloride TI 201 is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels.  It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical reexamination.  Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands.

CONTRAINDICATIONS: None known.

Important Safety Information:
 Following the administration of Thallous Chloride Tl 201  Injection, adverse anaphylactoid reactions have been reported (characterized by cardiovascular, respiratory, and cutaneous symptoms), some severe enough to require treatment.  Hypotension, pruritus, flushing and diffuse rash which responds to antihistamines have been reported.  Other reported events include itching, nausea/vomiting, mild diarrhea, tremor, shortness of breath, chills, fever, conjunctivitis, sweating and blurred vision.

WARNINGS:
In studying patients in whom myocardial infarction or ischemia is known or suspected, care should be taken to assure continuous clinical monitoring and treatment in accordance with safe, accepted procedure.  Exercise stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation equipment.
The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.

PRECAUTIONS:
Data are not available concerning the effect of marked alterations in blood glucose, insulin, or pH (such as is found in diabetes mellitus) on the quality of Thallous ­Chloride TI 201 Injection scans.  Attention is directed to the fact that thallium is a potassium analog, and since the transport of potassium is affected by these factors, the possibility exists that the thallium may likewise be affected.

General

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Thallous Chloride TI 201 Injection, as all radioactive materials, must be handled with care and used with appropriate safety measures to minimize external radiation exposure to patients and to clinical personnel. 

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Please see full Prescribing Information: Thallous Chloride Tl 201 Injection